Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Song, Huan ^a   Zhu, Jianwei ^b   Lu, Donghao ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ATROPHIC GASTRITIS; CELL HYPERPLASIA; CLINICAL EFFECTIVENESS; DRUG SAFETY; DYSPLASIA; ENTEROCHROMAFFIN LIKE CELL; EVIDENCE BASED MEDICINE; HUMAN; INTESTINE METAPLASIA; LONG TERM CARE; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; HYPERPLASIA; INTESTINE; MAINTENANCE CHEMOTHERAPY; META ANALYSIS; METAPLASIA; PATHOLOGY; PRECANCER; STOMACH TUMOR; TIME;

ENTEROCHROMAFFIN-LIKE CELLS; GASTRITIS, ATROPHIC; HUMANS; HYPERPLASIA; INTESTINES; MAINTENANCE CHEMOTHERAPY; METAPLASIA; PRECANCEROUS CONDITIONS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84925226708     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010623.pub2     Document Type: Review

References (90)

1. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35(5):590-8.
2. Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Alimentary Pharmacology and Therapeutics 2012;36(10):959-71.
3. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Alimentary Pharmacology and Therapeutics 1996;10(4):529-39.
4. Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group. Gastroenterology 1994;107(5):1305-11.
5. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257-65.
6. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257-65.
7. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. American Journal of Gastroenterology 2001;96(1):27-34.
8. Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117(2):319-26.
9. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257-65.
10. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Alimentary Pharmacology and Therapeutics 2001;5(7):927-35.
11. Gardner JD, Rindi G, Dayal Y, Fiocca R, Perdomo C, Jaskir J, et al. Evolution of Helicobacter pylori infection, gastritis and enterochromaffine-like cell hyperplasia in 443 patients with gastroesophageal reflux disease treated for one year with rabeprazole. Gastroenterology 1999;16(4 part 2):G0731.
12. Lundell L, Havu N, Miettinen P, Myrvold HE, Wallin L, Julkunen R, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Alimentary Pharmacology and Therapeutics 2006;23(5):639-47.
13. Meining A, Kiel G, Stolte M. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Alimentary Pharmacology and Therapeutics 1998;12(8):735-40.
14. Nishi T, Makuuchi H, Weinstein WM. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus. Tokai Journal of Experimental and Clinical Medicine 2005;30(2):117-21.
15. Richter J, Fraga P, Mack M, Dermovsesian A. Comparison of the clinical efficacy and safety of pantoprazole vs ranitidin over three years to prevent relapse in patients with healed erosive esophagitis. Gastroenterology 2003;124:A232.
16. Abraham NS. Proton pump inhibitors: potential adverse effects. Current Opinion in Gastroenterology 2012;28(6):615-20.
17. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs. ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Archives of Internal Medicine 2000;160(10):1455-61.
18. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. American Journal of Medicine 2009;112(10):896-903.
19. Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA 2010;303(17):1723-8.
20. Asfeldt AM, Straume B, Steigen SE, Løchen ML, Florholmen J, Bernersen B, et al. Changes in the prevalence of dyspepsia and Helicobacter pylori infection after 17 years: the Sørreisa gastrointestinal disorder study. European Journal of Epidemiology 2008;23(9):625-33.
21. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis (Statistics in Practice). Chichester: John Wiley & Sons, 2008.
22. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Alimentary Pharmacology & Therapeutics 2012;36(1):37-47.
23. Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics 2006;23(6):727-33.
24. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Research 1992;52(24):6735-40.
25. Dajani EZ. Gastroesophageal reflux disease: pathophysiology and pharmacology overview. Journal of the Association for Academic Minority Physicians 2000;11(1):7-11.
26. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Alimentary Pharmacology and Therapeutics 1999;13(2):179-86.
27. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2011;44(1):74-94.
28. Dixon MF, Genta RM, Yardley JH. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. American Journal of Surgical Pathology 1996;20:1161-81.
29. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112(3):707-17.
30. Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?. Archives of Iranian Medicine 2013;16(8):449-58.
31. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893-917.
32. Fiocca R, Mastracci L, Attwood S, Ell C, Galmiche J, Hatlebakk J, et al. Exocrine and endocrine gastric mucosal changes under medical or surgical antireflux therapy. Results of a 5-yr follow up in the lotus trial. Gastroenterology 2010;138(5):S649-50.
33. Fox JG, Kuipers EJ. Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Gut 2011;60(5):567-8.
34. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Annals of Internal Medicine 1994;121(3):232-3.
35. Fukao A, Hisamichi S, Ohsato N, Fujino N, Endo N, Iha M. Correlation between the prevalence of gastritis and gastric cancer in Japan. Cancer Causes Control 1993;4(1):17-20.
36. Geboes K, Dekker W, Mulder CJ, Nusteling K, Dutch Study Group. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Alimentary Pharmacology and Therapeutics 2001;15(11):1819-26.
37. Genta RM. Review article: gastric atrophy and atrophic gastritis - nebulous concepts in search of a definition. Alimentary Pharmacology and Therapeutics 1998;12(Suppl 1):17-23.
38. Genta RM, Rindi G, Fiocca R, Magner DJ, D'Amico D, Levine DS. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. American Journal of Gastroenterology 2003;98(6):1257-65.
39. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEprofiler (GRADEpro). 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
40. Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Endoscopy 2003;35(2):112-7.
41. Hassall E, Owen D, Kerr W, Sturby T, Richardson P, El-Serag H. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Alimentary Pharmacology and Therapeutics 2011;33(7):829-36.
42. Held M. Epidemiological Studies of Helicobacter pylori and its Relation to Cancer and Precancerous Lesions in the Upper Gastrointestinal Tract. Stockholm: Karolinska Institutet, 2004.
43. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95(4):903-12.
44. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
45. Holt S, Howden CW. Omeprazole: overview and opinion. Digestive Diseases and Sciences 1991;36(4):385-93.
46. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. American Journal of Gastroenterology 2007;102(3):497-506.
47. Hwang JH, Rulyak SD, Kimmey MB. American Gastroenterological Association Institute technical review on the management of gastric subepithelial masses. Gastroenterology 2006;130(7):2217-28.
48. Jianu CS, Fossmark R, Viset T, Qvigstad G, Sørdal O, Mårvik R, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Alimentary Pharmacology & Therapeutics 2012;31(7):644-9.
49. Johnson DA, Oldfield EC 4th. Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clinical Gastroenterology and Hepatology 2013;11(5):458-64.
50. Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. Journal of the Egyptian Society of Parasitology 1998;28(1):149-57.
51. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. Journal of Clinical Gastroenterology 2003;36(5 Suppl):S29-36, S61-2.
52. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118(4):661-9.
53. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. New England Journal of Medicine 1996;334(16):1018-22.
54. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53(1):12-20.
55. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955-60.
56. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology and Therapeutics 2000;14(6):651-68.
57. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001;64(4):205-13.
58. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathologica et Microbiologica Scandinavica 1965;64:31-49.
59. Lee SW, Lieberman DA, Ippoliti AD, Hsieh CY, Weinstein WM. Changes in the parietal cell mass after long-term therapy with high dose omeprazole in Barrett's esophagus (BE). Gastroenterology 1996;110:A173.
60. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56(6):772-81.
61. Marks RD, Richter JE, Rizzo J. Omeprazole vs. H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106(4):907-15.
62. McColl KEL, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:239.
63. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5(4):206-14.
64. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996;312(7028):414-5.
65. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. New England Journal of Medicine 1999;341(9):635-44.
66. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. Endoscopic regression of Barrett's oesophagus during omeprazole therapy. Gut 1999;45(4):489-94.
67. Pounder RE, Williams MP. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000;118:238-9.
68. Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. European Journal of Gastroenterology and Hepatology 1995;7(7):661-5.
69. Price AB. The Sydney System: histological division. Journal of Gastroenterology and Hepatology 1991;6(3):209-22.
70. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
71. Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association?. Journal of Gastroenterology 1995;30(6):775-8.
72. Richter J, Kahrilas P, Hwang C, Marino V, Hamelin B. Six month safety and tolerability of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE). Gastroenterology 2000;118(4 part 2):A1299.
73. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. European Journal of Gastroenterology and Hepatology 2005;17(5):559-66.
74. Rostom A, Dube C, Wells GA, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002296]
75. Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Alimentary Pharmacology and Therapeutics 1999;13(2):145-53.
76. Sanduleanu S, Jonkers D, De Bruïne A, Hameeteman W, Stockbrügger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Alimentary Pharmacology and Therapeutics 2001;15(8):1163-75.
77. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena E, Nelis GF, Festen HP, et al. Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 1998;12(7):605-12.
78. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000;46(5):615-21.
79. Shiota S, Murakawi K, Suzuki R, Fujioka T, Yamaoka Y. Helicobacter pylori infection in Japan. Expert Review of Gastroenterology and Hepatology 2013;7(1):35-40.
80. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scandinavian Journal of Gastroenterology 2007;42(1):2-10.
81. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988;41(4):185-200.
82. Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. American Journal of Surgical Pathology 1995;19(Suppl 1):S1-7.
83. Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. Journal of Clinical Biochemistry and Nutrition 2008;42(2):71-5.
84. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World Journal of Gastroenterology 2010;16(19):2323-30.
85. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Mashiba H, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Alimentary Pharmacology and Therapeutics 2000;14(10):1345-52.
86. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux esophagitis. New England Journal of Medicine 1995;333(17):1106-10.
87. Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion - clinical perspectives. Acta Physiologica 2014;210:239-56.
88. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar lined Barrett's oesophagus with omeprazole 40 mg daily: results of 5 years continuous therapy. Alimentary Pharmacology and Therapeutics 1999;13(9):1205-9.
89. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(2 Suppl 1):S9-31.
90. Eslami L, Kalantarian S, Nasseri-Moghaddam S, Majdzadeh R. Long term proton pump inhibitor (PPI) use and incidence of gastric (pre) malignant lesions. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD007098.pub2]